We were founded to leverage the groundbreaking research of our Co-Founder and Chief Scientific Officer, Professor Robin Shaw M.D., Ph.D., and his team at the Nora Eccles Harrison Cardiovascular Research and Training Institute at the University of Utah
Hebrew for “Repairing the Heart”
TLT-101 is a precision therapy designed to target the underlying biology of failing heart muscle
Comprehensive preclinical studies demonstrate an unprecedented efficacy and safety profile with a one-time low IV dose
We have the unique ability to leverage a blood-based biomarker to enable a precision therapy paradigm